Carbetocin

證據等級: L5

預測適應症: 2 個

Carbetocin: From Postpartum Hemorrhage to Isotretinoin-Like Syndrome

One-Sentence Summary

Carbetocin is a synthetic long-acting oxytocin analogue, primarily used to prevent uterine atony and postpartum hemorrhage by activating oxytocin receptors in the myometrium. The TxGNN model predicts it may be effective for isotretinoin-like syndrome, yet no clinical trials and no publications currently support this direction. This prediction rests on model output alone (Evidence Level L5), with mechanistic analysis revealing no plausible biological link.

Quick Overview

Item	Content
Original Indication	Postpartum hemorrhage prevention (uterine atony)
Predicted New Indication	Isotretinoin-Like Syndrome
TxGNN Prediction Score	99.15%
Evidence Level	L5
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Carbetocin is a synthetic, long-acting oxytocin analogue that binds selectively to the G protein-coupled oxytocin receptor (OTR). Upon receptor activation, it triggers the Gq → PLC → IP3/DAG → PKC intracellular cascade, elevating cytosolic calcium and driving uterine smooth muscle contraction — the pharmacological mechanism underlying its clinical use in preventing postpartum hemorrhage after cesarean delivery.

Isotretinoin-like syndrome describes an embryotoxic phenotype caused by excess retinoic acid (13-cis-retinoic acid) exposure. Its molecular basis is entirely distinct: aberrant activation of RAR/RXR nuclear receptors disrupts neural crest cell migration, producing characteristic craniofacial, cardiac, and thymic developmental defects. The receptor systems (GPCR vs. nuclear receptor), downstream effectors (Ca²⁺/PKC vs. gene transcription), and target biology (uterine contractility vs. embryonic organogenesis) have no established points of intersection in the pharmacological literature.

The high TxGNN score (99.15%) most likely reflects indirect statistical co-occurrence between sparse nodes in the knowledge graph, rather than a biologically meaningful repurposing signal. No experimental, mechanistic, or clinical data have been identified to support this predicted indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Philippines Market Information

Carbetocin is not currently registered in the Philippines. No active product licenses were found in the regulatory database.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical or preclinical evidence supporting Carbetocin for isotretinoin-like syndrome, and mechanistic analysis reveals a fundamental mismatch between the oxytocin receptor/Ca²⁺ signaling axis and the RAR/RXR-driven retinoic acid teratogenicity pathway. This prediction does not meet the minimum threshold for further investigation.

To proceed, the following would be needed:

A credible biological hypothesis linking OTR activation to retinoic acid signaling or neural crest cell biology
Preclinical data (in vitro or animal model) demonstrating any effect of oxytocin receptor agonism on retinoic acid-induced toxicity
Full safety profile including package insert warnings and contraindications (currently unavailable)
Reconsideration of whether this TxGNN result is a spurious knowledge-graph artefact arising from rare-node proximity, rather than a true repurposing signal

Note: The second-ranked prediction, Goodman syndrome (TxGNN score 99.06%, rank 6178), is similarly unsupported — it involves the RAB23/Sonic Hedgehog/Gli signaling axis, which has no known pharmacological intersection with the oxytocin receptor pathway. Both top predictions share the same L5 / Hold classification and warrant no near-term development resources.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.